WO2019145784A3 - Combination therapies for multi-drug resistant pathogens - Google Patents

Combination therapies for multi-drug resistant pathogens Download PDF

Info

Publication number
WO2019145784A3
WO2019145784A3 PCT/IB2019/000083 IB2019000083W WO2019145784A3 WO 2019145784 A3 WO2019145784 A3 WO 2019145784A3 IB 2019000083 W IB2019000083 W IB 2019000083W WO 2019145784 A3 WO2019145784 A3 WO 2019145784A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug resistant
combination therapies
resistant pathogens
pathogens
methods
Prior art date
Application number
PCT/IB2019/000083
Other languages
French (fr)
Other versions
WO2019145784A2 (en
Inventor
Young Lag Cho
Ja Seong Koo
Jeong Yul Yun
Kyu Man Oh
Jeung Soon Choi
Chul-Woong CHUNG
Dae Hyuck KANG
Hyun Jin Kwon
Yong Zu Kim
Original Assignee
Legochem Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legochem Biosciences, Inc. filed Critical Legochem Biosciences, Inc.
Publication of WO2019145784A2 publication Critical patent/WO2019145784A2/en
Publication of WO2019145784A3 publication Critical patent/WO2019145784A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides pharmaceutical compositions and methods for treating multi-drug resistant pathogens.
PCT/IB2019/000083 2018-01-26 2019-01-25 Combination therapies for multi-drug resistant pathogens WO2019145784A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622327P 2018-01-26 2018-01-26
US62/622,327 2018-01-26

Publications (2)

Publication Number Publication Date
WO2019145784A2 WO2019145784A2 (en) 2019-08-01
WO2019145784A3 true WO2019145784A3 (en) 2019-09-06

Family

ID=67394552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/000083 WO2019145784A2 (en) 2018-01-26 2019-01-25 Combination therapies for multi-drug resistant pathogens

Country Status (1)

Country Link
WO (1) WO2019145784A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541176A (en) * 1994-07-20 1996-07-30 Merck & Co., Inc. 3-thioheteroaryl cephalosporin compounds, compositions and methods of use
US7129232B2 (en) * 2002-10-30 2006-10-31 Astellas Pharma Inc. Cephem compounds
CN101230070A (en) * 2006-12-30 2008-07-30 黄振华 Novel anti-infection cephalosporin compounds
US8329684B2 (en) * 2011-03-30 2012-12-11 Legochem Biosciences, Inc. Cephalosporin derivatives and pharmaceutical compositions thereof
WO2013149136A1 (en) * 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. ISOXAZOLE β-LACTAMASE INHIBITORS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541176A (en) * 1994-07-20 1996-07-30 Merck & Co., Inc. 3-thioheteroaryl cephalosporin compounds, compositions and methods of use
US7129232B2 (en) * 2002-10-30 2006-10-31 Astellas Pharma Inc. Cephem compounds
CN101230070A (en) * 2006-12-30 2008-07-30 黄振华 Novel anti-infection cephalosporin compounds
US8329684B2 (en) * 2011-03-30 2012-12-11 Legochem Biosciences, Inc. Cephalosporin derivatives and pharmaceutical compositions thereof
WO2013149136A1 (en) * 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. ISOXAZOLE β-LACTAMASE INHIBITORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM, Y.-Z. ET AL.: "Synthesis and antibacterial activities of novel C(7)-Catechol-substituted cephalosporins (II", THE JOURNAL OF ANTIBIOTICS, vol. 49, no. 5, 1996, pages 499 - 501, XP002733529, doi:10.7164/antibiotics.49.496 *

Also Published As

Publication number Publication date
WO2019145784A2 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
MX2020005772A (en) Compositions comprising bacterial blautia strains for treating visceral hypersensitivity.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2018015761A (en) Compositions comprising bacterial strains.
WO2017027810A3 (en) Compositions and methods that promote the hypoxia response for treatment of mitochondrial dysfunction and oxidative stress disorders
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
WO2017218949A3 (en) Peptidomimetic macrocycles and uses thereof
MX2024008963A (en) Blood plasma fractions as a treatment for aging-associated cognitive disorders.
WO2015120062A3 (en) Therapeutic compounds and compositions
WO2017106364A3 (en) Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
IL283539A (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
ZA202101362B (en) Compositions and methods for treating the eye
WO2016167944A3 (en) Compositions and methods for treating autism
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
EP3740246A4 (en) Disrupting the linc complex for treating laminopathy
EP3801478A4 (en) Methods and compositions for preventing or treating calciphylaxis
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA48939B1 (en) Compositions comprising bacterial strains
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
WO2017120527A3 (en) Therapeutic compositions and methods for treating hepatitis b
WO2016181220A3 (en) Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof
WO2021024133A3 (en) Biopharmacuetical compositions and related methods
WO2016130581A3 (en) Combination cancer therapy
WO2018094106A3 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
MX2019015280A (en) Statin compositions and methods for use in treating synucleinopathies.
WO2016193945A3 (en) Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19743992

Country of ref document: EP

Kind code of ref document: A2